Sports Tech Innovator Enhanced Set to Go Public in Landmark $1.2 Billion Nasdaq SPAC Deal
The Psychedelic Revolution: Angermayer's Atai Life Sciences Eyes Nasdaq with a $1.2 Billion SPAC Deal
Nasdaq's Bold New Play: A $1.2 Billion Bet on Innovation Through a Landmark SPAC Deal